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Abstract: The biological activities of sequential combinations of anticancer drugs, SOS thiophene
(SOS) and mesochlorin e6 monoethylenediamine (Mce6), in the form of free drugs, nontargeted
N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates, P-GFLG-Mce6 and P-
GFLG-SOS (P is the HPMA copolymer backbone and GFLG is the glycylphenylalanylleucylglycine
spacer), and Fab′ -targeted HPMA copolymer-drug conjugates, P-(GFLG-Mce6)-Fab′ and P-(GFLG-
SOS)-Fab′ (Fab′ from OV-TL16 antibodies complementary to CD47), were evaluated against human
ovarian carcinoma OVCAR-3 cells. Mce6, SOS, P-GFLG-Mce6, P-GFLG-SOS, P-(GFLG-Mce6)-
Fab′ , and P-(GFLG-SOS)-Fab′ , when used as single agents or in binary combination, exhibited
cytotoxic activities against OVCAR-3 cells, as determined using a modiﬁed MTT assay. The binding
and internalization of P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ by OVCAR-3 cells were
visualized by confocal microscopy and ﬂow cytometry. The results conﬁrmed an enhanced
biorecognition by OVCAR-3 cells of Fab′ -targeted HPMA copolymer conjugates over nontargeted
conjugates. The median-effect analysis and the determination of the combination index (CI) were
used to describe the drug interaction and quantify the synergism, antagonism, or additivity in
anticancer effects. The sequential combinations of SOS+Mce6 and P-GFLG-SOS+P-GFLG-Mce6
displayed very strong synergism to synergism in the entire range of cell inhibition levels (fa ) 0.5 -
0.95). The P-(GFLG-SOS)-Fab′ +P-(GFLG-Mce6)-Fab′ exhibited a strong synergism for fa values
up to about 0.85, but showed synergistic effect and nearly additive effect at fa ) 0.9 and 0.95,
respectively. These observations support the continuation of in vivo investigations of these conjugates
for the treatment of ovarian cancer.
Keywords: N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer; Fab′ antibody fragment;
2,5-bis(5-hydroxymethyl-2-thienyl)furan; mesochlorin e6 monoethylenediamine; combination
index; ovarian cancer
Introduction
Polymer-drug conjugates are established as one of the ﬁrst-
generation nanomedicines for the treatment of cancer. Their use
facilitates the uptake and transport of therapeutic agents and
creates a dose-differentiation between the treatment target and
the rest of the body, due to the fact that macromolecules can
accumulate passively in solid tumor tissue by the phenomenon
called “enhanced permeability and retention (EPR) effect”.
1 The
enhanced drug accumulation in tumor tissue increases the
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2-4
Moreover, the intracellular trafﬁcking mechanism of polymer-
drug conjugates renders drug efﬂux pumps ineffective.
5 To
obtain such multifunctional capabilities, polymer-drug conju-
gates have been designed to consist of (a) a nonimmunogenic
and biocompatible water-soluble polymer backbone such as
poly(ethylene glycol) or N-(2-hydroxypropyl)methacrylamide
(HPMA) copolymers,
6 (b) therapeutically active molecules, (c)
linkers between the polymer backbone and the active molecule
that are stable in blood circulation and release the free drug at
target sites, and (d) a targeting moiety to mediate biomolecular
recognition.
7,8 HPMA copolymers are one of the most fre-
quently evaluated polymer backbones in polymer-drug con-
jugates. The main advantages of HPMA copolymer-drug
conjugates over their low molecular weight drugs (reviewed in
Kopec ˇek,
6 Putnam and Kopec ˇek,
8 Kopec ˇek et al.,
5 Duncan,
9
Cuchelkar and Kopec ˇek,
10 Pan and Kopec ˇek
11) include the
following: (1) enhanced water solubility of poorly soluble or
insoluble drugs with concomitant improvement of drug bio-
availability; (2) long-lasting circulation in the bloodstream;
12,13
(3) decreased nonspeciﬁc toxicity of the conjugated drug and
immunogenicity of the targeting moiety;
14 (4) increased passiVe
and/or actiVe accumulation of the drug at the site of its action
by the EPR effect and/or by targeting, respectively;
15-17 (5)
active uptake by ﬂuid-phase pinocytosis (nontargeted polymer-
bound drug) or receptor-mediated endocytosis (targeted polymer
bound drug); (6) the potential to overcome efﬂux pump-
mediated mechanism of drug resistance;
18-20 and (7) ability to
deliver several active components with different properties to
the same target site that enhance the speciﬁc activity of the main
drug.
21,22 The incorporation of targeting moieties, such as
monoclonal antibody (mAb) or antibody fragment, into HPMA
copolymer-drug conjugates results in speciﬁc delivery and
enhancement of the amount of the polymeric conjugate being
internalized by receptor-mediated endocytosis.
23 Consequently,
the intracellular concentration of the polymeric conjugates is
enhanced with concomitant increase in antitumor activity.
17
Moreover, the polymer modiﬁcation of mAb or antibody
fragments reduces their immunogenicity and extends their
circulating half-lives.
14,24 The use of antibody fragments
provides a better control of the structure of HPMA copolymer
conjugates compared to full-length mAb. The unique sulfhydryl
group near the C terminus of Fab′ fragments has provided a
convenient way for coupling to HPMA copolymers containing
maleimide groups and allow the antigen-binding site to be more
approachable.
25,26
(3) Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat.
ReV. Cancer 2006, 6 (9), 688–701.
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317 (5842), 1182–1183.
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action. Eur. J. Pharm. Biopharm. 2000, 50 (1), 61–81.
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toxicity of anticancer agents, a novel concept of combining
chemotherapy and photodynamic therapy (PDT), using
HPMA copolymer bound drugs, was developed.
27 The in
ViVo studies on two cancer models, Neuro 2A neuroblastoma
induced in A/J mice
28 and human ovarian carcinoma
heterotransplanted in nude mice,
17,29,30 demonstrated that
combination therapy with HPMA copolymer-bound DOX
(doxorubicin) and HPMA copolymer-bound Mce6 (meso-
chlorin e6 monoethylenediamine) produced tumor cures
which could not be obtained with either chemotherapy or
PDT alone. Furthermore, signiﬁcantly lower nonspeciﬁc
toxicities were observed when compared to low molecular
weight drugs. Previously, in Vitro studies of the binary
combination of free and HPMA copolymer-bound SOS [2,5-
bis(5-hydroxymethyl-2-thienyl)furan, NSC 652287], DOX,
and Mce6 in the treatment of human A498 renal carcinoma
cells using the median-effect method showed that these
combinations displayed synergistic-to-additive effects, de-
pending on the cytotoxic mechanisms of each agent.
31
In the present study, Fab′ -targeted and nontargeted HPMA
copolymer-drug (SOS and Mce6) conjugates for combina-
tion chemotherapy and PDT against human ovarian OVCAR-3
carcinoma cells were synthesized. SOS, a dithiophene
compound, was used as the chemotherapy agent. Its mech-
anism of action consists of disrupting the p53-HDM-2
(human double minute-2) interaction, resulting in an in-
creased p53 accumulation, thereby inducing cell cycle arrest
and apoptosis.
32-35 For PDT the second-generation synthetic
photosensitizer, Mce6, was used. Photosensitizer molecules
can be activated by speciﬁc wavelength of light and interact
with molecular oxygen to produce reactive singlet oxygen,
causing irreversible photodamage to cells resulting in cell
death.
36 The antibody Fab′ fragment was prepared from OV-
TL16 antibody, which recognizes the OA-3 surface antigen,
also known as CD47 or IAP (integrin-associated protein),
37,38
overexpressed on most human ovarian carcinoma cells.
39,40
It was hypothesized that a combination of these agents
may produce synergistic effects and has higher efﬁciency
than each agent alone. Accordingly, the efﬁciency of free,
nontargeted, and Fab′ fragment-targeted HPMA copolymer-
bound SOS and Mce6 against OVCAR-3 cells as single
agents and in combination was evaluated. The combination
index (CI) analysis was used to quantify the synergism,
antagonism, and additive effects of drug combinations.
41-43
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Materials. Mce6 was purchased from Porphyrin Products
(Logan, UT). SOS was kindly supplied by the Drug Synthesis
and Chemistry Branch, Developmental Therapeutics Pro-
gram, Division of Cancer Treatment and Diagnosis, National
Cancer Institute. All other chemicals were purchased from
Sigma Chemical Co. (St. Louis, MO).
Cell Line. The human ovarian carcinoma cell line
OVCAR-3 was purchased from American type Culture
Collection. Cells were cultured in RPMI 1640 medium
(Sigma) containing 10 µg/mL insulin (Sigma) supplemented
with 10% fetal bovine serum (HyClone Laboratories, Logan,
UT), at 37 °C in a humidiﬁed atmosphere of 5% CO2 (v/v).
OV-TL16 Antibody Production. The OV-TL16 antibody
was produced as described previously.
44 Brieﬂy, the OV-
TL16 antibody was produced by in Vitro cartridge bioreactor
(Cellulosic-MPS, Spectrum Laboratories, Rancho Domingu-
ez, CA) culture of OV-TL16 hybridoma cells with serum
free hybridoma medium (Gibco Life Sciences, Carlsbad,
CA). The antibody was puriﬁed by applying the supernatant
of cell suspension harvested from bioreactor to a protein G
Sepharose 4 Fast Flow column (Pharmacia, Piscataway, NJ),
equilibrated with binding buffer (0.01 M Na2HPO4, 0.15 M
NaCl, 0.01 M EDTA pH 7.2). The OV-TL16 antibody was
eluted with 0.5 M acetate buffer pH 3.0. The antibody was
dialyzed (mol wt cutoff 6-8 kDa) against phosphate buffered
saline (PBS) overnight at 4 °C.
Preparation of Fab′ Fragment. The antibody Fab′
fragment was prepared freshly as described previously.
25,44
The OV-TL16 antibody in 0.1 M citric buffer pH 4.0 was
digested by 10% (w/w) pepsin (Sigma) for 2.5 h at 37 °Ct o
give F(ab′ )2. The digestion reaction was monitored by size
exclusion chromatography on a Superdex 200 column. The
F(ab′ )2 was reduced to Fab′ with 20 mM cysteine (Sigma)
in 20 mM Tris buffer pH 8.5 for1ha t3 7°C. Excess cysteine
was removed on a Sephadex G-25 (PD-10 column, Phar-
macia).
Synthesis of Nontargeted HPMA Copolymer-Mce6
Conjugate (P-GFLG-Mce6). P-GFLG-Mce6 was prepared
as described previously.
28 Brieﬂy, the conjugate was syn-
thesized using a polymer analogous reaction in two steps.
First, the polymer precursor (P-GFLG-ONp) was prepared
by radical precipitation copolymerization of HPMA and
N-methacryloylglycylphenylalanylleucylglycine p-nitrophe-
nyl ester (MA-GFLG-ONp).
45,46 Second, Mce6 was bound
to P-GFLG-ONp by aminolysis of reactive ONp groups in
N,N-dimethylformamide (DMF). The reaction solution was
precipitated into a mixture of acetone:ether (3:2 (v/v)). The
dried precipitate was dissolved in methanol and puriﬁed on
a Sephadex LH-20 column with methanol/0.5% acetic acid
as the elution solvent. The polymer band was collected and
evaporated to dryness. The product was dissolved in deion-
ized (DI) water, dialyzed overnight and lyophilized. The
product yield was 69%. The structure and characterization
of nontargeted polymer conjugates are summarized in
Scheme 1A and Table 1.
Synthesis of Nontargeted HPMA Copolymer-SOS
Conjugate (P-GFLG-SOS). P-GFLG-SOS (Scheme 1A)
was synthesized by binding of SOS to the P-GFLG-ONp
polymer precursor via an ester linkage.
31 Brieﬂy, P-GFLG-
ONp was dissolved in DMF and mixed with DMF solution
of SOS. 4-Dimethylaminopyridine (DMAP) was added, and
the reaction was allowed to proceed for 72 h in the dark at
room temperature. The product was isolated, after reduction
of volume, by precipitation into a mixture of acetone:ether
(3:1 (v/v)). The precipitate was dissolved in methanol and
applied to a Sephadex LH-20 column with methanol as the
mobile phase. The polymer band was collected, concentrated
and reprecipitated. The product was a yellowish powder, with
a yield of 61%.
Synthesis of HPMA Copolymer-Mce6 Conjugate
Containing Maleimide Groups, P-(GFLG-Mce6)-MAL.
This copolymer precursor was prepared in three steps. The
reactions are shown in Scheme 2. First, a polymerizable
derivative of Mce6, N-methacryloylglycylphenylala-
nylleucylglycine Mce6 (MA-GFLG-Mce6),
25 was synthesized
by reacting MA-GFLG-ONp (60 mg, 0.103 mmol) with Mce6
(63.5 mg, 0.093 mmol) in DMF (∼2 mL). The reaction
solution was stirred at room temperature in the dark for 2 h.
N,N′ -diisopropylethylamine (DIPEA; 18 µL, 0.103 mmol)
was added and stirring continued overnight. 1-Amino-2-
propanol (∼8 µL, 0.103 mmol) and a small amount of tert-
octylpyrocatechol were added and DMF was removed under
reduced pressure. The residue was isolated using a Sephadex
LH-20 column with acetone:methanol:acetic acid (2:1:0.1)
as the mobile phase. The fractions were collected and
checked on TLC. The product fraction was evaporated to
dryness, washed with ether, collected by ﬁltration, and dried
under vacuum. The molecular weight (Mw) of MA-GFLG-
Mce6 was 1083.6 Da as determined by electrospray ionization
mass spectrometry (ESI-MS). The product yield was 90 mg
(73%). Second, the polymeric precursor P-(GFLG-Mce6)-
NH2 was prepared by radical copolymerization of HPMA
47
(107.6 mg, 0.751 mmol), N-(3-aminopropyl)methacrylamide
hydrochloride (APMA, 16.27 mg, 0.091 mmol; Polysciences,
Warrington, PA), and MA-GFLG-Mce6 (76.9 mg, 0.068
mmol) in methanol (∼1.8 mL) at 50 °C for 48 h, using 2,2′ -
azobisisobutyronitrile (AIBN; 19.27 mg) as the initiator. The
polymerization mixture contained 12.5 wt % of monomers
and 1.2 wt % of AIBN. The molar ratio of HPMA:APMA:
(44) Lu, Z. R. Polymerizable Fab′ antibody fragment targeted photo-
dynamic cancer therapy in nude mice. S.T.P. Pharma Sci. 2003,
13 (1), 69–75.
(45) Kopec ˇek, J.; Rejmanova ´, P.; Strohalm, J.; Ulbrich, K.; R ˇı ´hova ´,
B.; Chytry ´, V.; Lloyd, J.; Duncan, R. Synthetic polymeric drugs.
U.S. 5,037,883(Aug. 6, 1991).
(46) Ulbrich, K.; S ˇubr, V.; Strohalm, J.; Plocova ´, D.; Jelı ´nkova ´, M.;
R ˇı ´hova ´, B. Polymeric drugs based on conjugates of synthetic and
natural macromolecules. I. Synthesis and physico-chemical char-
acterisation. J. Controlled Release 2000, 64 (1-3), 63–79.
(47) Kopec ˇek, J.; Baz ˇilova ´, H. Poly[N-(2-hydroxypropyl)methacryla-
mide]. I. Radical polymerization and copolymerization. Eur.
Polym. J. 1973, 9 (1), 7–14.
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puriﬁed on a Sephadex LH-20 column eluted with methanol.
The polymer fraction was collected, and methanol was
evaporated. The residue was precipitated in a mixture of
acetone:ether (1:2 (v/v)). The precipitate was dissolved in
water, dialyzed (mol wt cutoff 6-8 kDa) against DI water
Scheme 1. Chemical Structures of (A) Nontargeted and (B) Fab′ -Targeted HPMA Copolymer-Mce6 or -SOS Conjugates
Table 1. Characterization of Nontargeted HPMA Copolymer Conjugates, Polymeric Precursors, and Fluorescently Labeled
HPMA Copolymer Conjugates
structures
m o l%o f
side chains
a
mmol of ligand/
g of polymer
conjugate
no. of ligands/
polymer chain
(conjugate)
apparent
Mw (kDa)
b
P-GFLG-Mce6 2.04 0.125 2.9 23
P-GFLG-SOS 1.62 0.106 3.4 32
P-(GFLG-Mce6)-NH2 2.62 0.153 (Mce6) 1.7 (Mce6) 11
8.11
c 0.472 (NH2)
P-(GFLG-SOS)-NH2 4.60 0.270 (SOS) 2.7 (SOS) 10
4.70
c 0.272 (NH2)
P-(GFLG-Mce6)-MAL 2.60 0.142 (Mce6) 2.0 (Mce6) 14
6.02
d 0.329 (MAL)
P-(GFLG-SOS)-MAL 4.14 0.236 (SOS) 5.2 (SOS) 22
3.36
d 0.192 (MAL)
P-(GFLG-Mce6)-FITC f 0.060
e 1.0 (FITC) f
P-(GFLG-SOS)-FITC f 0.038
e 0.6 (FITC) f
P-(GFLG-Mce6)-(Fab′ -FITC)
g f 0.063
e 3.1 (FITC per conjugate) f
P-(GFLG-SOS)-(Fab′ -FITC)
g f 0.050
e 2.5 (FITC per conjugate) f
a Determined by UV spectrophotometry in methanol: ε395 ) 158000 M
-1 cm
-1 for Mce6, and ε358 ) 33000 M
-1 cm
-1 for SOS.
b Apparent
molecular weight (Mw) of polymers was estimated by size exclusion chromatography using AKTA/FPLC (Pharmacia) system equipped with a
Superose 6 column, calibrated with polyHPMA fractions. PBS buffer pH 7.3 + 30% (v) acetonitrile and 0.1 M acetate buffer pH 5.5 + 30%
(v) acetonitrile were used for polymer conjugates containing Mce6 and polymer conjugates containing SOS, respectively.
c Determined by
ninhydrin assay.
d Determined by 5-((2-(and-3)-S-(acetylmercapto)succinoyl)amino)ﬂuorescein assay (SAMSA assay, Molecular Probes).
e Determined by spectrophotometric determination of FITC (ε497 ) 73 000 M
-1 cm
-1 in 0.1 M sodium borate buffer).
f Not determined.
g Fluorescently labeled targeted conjugates were prepared by reacting P-(GFLG-Mce6)-Fab′ and P- (GFLG-SOS)-Fab′ (Table 2) with 5-SFX.
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polymeric precursor P-(GFLG-Mce6)-MAL was prepared by
reacting P-(GFLG-Mce6)-NH2 (55 mg, 0.026 mmol NH2
group) with succinimidyl trans-4-(maleimidomethyl)cyclo-
hexane-1-carboxylate (SMCC; 17.36 mg, 0.052 mmol)
(Soltec Ventures, Beverly, MA) and DIPEA (∼13 µL, 0.078
mmol). The mole ratio of NH2:SMCC:DIPEA was 1:2:3.
P-(GFLG-Mce6)-NH2 was dissolved in 0.3 mL of DMF and
SMCC in 0.9 mL of DMF. The polymer solution was added
into the SMCC solution. DIPEA was added dropwise. The
reaction solution was stirred overnight at room temperature.
DMF was removed under reduced pressure to dryness. The
residue was dissolved in a small volume of methanol and
puriﬁed on a Sephadex LH-20 column eluted with a mixture
of methanol and 0.1% acetic acid. The copolymer band was
collected, evaporated and precipitated into a mixture of
acetone:ether (1:1). The characterization of copolymer
precursors is shown in Table 1.
Synthesis of HPMA Copolymer-SOS Conjugate
Containing Maleimide Groups, P-(GFLG-SOS)-MAL.
This copolymer precursor was also prepared by three-step
reaction. The procedure is shown in Scheme 2. First, MA-
GFLG-ONp (278.6 mg, 0.480 mmol) and SOS (200 mg,
0.680 mmol) were dissolved in tetrahydrofuran (THF; ∼15
mL). DMAP (44.6 mg, 0.370 mmol) was added. The reaction
mixture was stirred at room temperature in the dark for 72 h.
The mixture was concentrated under reduced pressure. The
residue was isolated using silica gel column chromatography.
The excess free drug was recovered by elution with acetone:
hexane (2:1), and the fractions were collected by eluting with
acetone and then with methanol. The fractions were checked
on TLC. The product-containing fraction was evaporated and
recrystallized with THF/hexane. The Mw of MA-GFLG-SOS
was 734.2 Da as determined by ESI-MS. The product yield
was 130 mg (27%). Second, polymeric precursor, P-(GFLG-
SOS)-NH2, was synthesized by copolymerization of HPMA
(141.3 mg, 0.987 mmol), APMA (14.2 mg, 0.079 mmol),
and MA-GFLG-SOS (50 mg, 0.068 mmol) in DMF (1 mL)
and acetone (0.5 mL) at 50 °C for 48 h, using AIBN (19.7
mg) as the initiator. The molar ratio of HPMA:APMA:MA-
GFLG-SOS was 87:7:6. The reaction mixture was puriﬁed
on a Sephadex LH-20 column eluted with methanol. The
polymer fraction was collected and evaporated to the viscous
residue. The residue was precipitated into acetone:ether (1:
1). The product yield was 150 mg (73%). Third, polymeric
precursor P-(GFLG-SOS)-MAL was prepared by using the
same procedure as for P-(GFLG-Mce6)-MAL. P-(GFLG-
SOS)-NH2 (145 mg, 0.040 mmol NH2 groups) and SMCC
(26.41 mg, 0.079 mmol) were dissolved separately in DMF
(∼2.5 mL and ∼0.5 mL, respectively). DIPEA (∼21 µL,
0.119 mmol) was used. The product was applied on a
Sephadex LH-20 column and eluted with methanol without
acetic acid. The product was precipitated and ﬁltered off,
with a yield of 130 mg (76%). The characterization of
conjugates is shown in Table 1.
Preparation of Antibody Fab′ Fragment-Targeted HPMA
Copolymer-Mce6/-SOS Conjugates, P-(GFLG-Mce6)-Fab′
and P-(GFLG-SOS)-Fab′ . The targeted conjugates were
prepared by dissolving P-(GFLG-Mce6)-MAL or P-(GFLG-
SOS)-MAL precursor in 20 mM MES buffer pH 6.5 and
reacting with freshly prepared Fab′ fragment (polymer:Fab′
weight ratio ) 1:2) overnight in the dark at 4 °C. The product
was puriﬁed on a DEAE Sepharose Fast Flow ion exchange
column (Pharmacia), eluted using 20 mM Bis-Tris buffer
pH 6.5 with a gradient NaCl concentration of 0-0.5 M. The
fraction corresponding to conjugate was conﬁrmed by size
exclusion chromatography using Superose 6 (HR 10/30)
column. The structure and composition of polymer conju-
gates are summarized in Scheme 1B and Table 2.
Preparation of Fluorescein-Labeled Nontargeted HPMA
Copolymer-Mce6/-SOS Conjugates, P-(GFLG-Mce6)-
FITC and P-(GFLG-SOS)-FITC. 6-(Fluorescein-5-carboxa-
mido)hexanoic acid succinimidyl ester (5-SFX; ∼0.1 mg,
0.170 µmol) was dissolved in dimethylsulfoxide (25 µL) and
DI water (100 µL). The polymer precursor P-(GFLG-Mce6)-
NH2 or P-(GFLG-SOS)-NH2 (∼3 mg, ∼1 µmol of NH2) was
dissolved in DI water (∼300 µL). The 5-SFX solution was
added into the polymer solution. DIPEA (∼1 drop) was
added into the reaction solution while stirring. The mixture
was stirred at room temperature in the dark for 1 h. Saturated
Na2HPO4 (∼20 µL) was added to stop the reaction. The
product was separated on a PD-10 column and eluted with
PBS.
Preparation of Fluorescein-Labeled Fab′ -Targeted HPMA
Copolymer-Mce6/-SOS Conjugates, P-(GFLG-Mce6)-
(Fab′ -FITC) and P-(GFLG-SOS)-(Fab′ -FITC). P-(GFLG-
Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ were reacted with
5-SFX. The procedure was as described for P-(GFLG-Mce6)-
FITC and P-(GFLG-SOS)-FITC. The characterization of
ﬂuorescently labeled copolymer conjugates is shown in
Table 1.
Drug Stock Solution Preparations. SOS was dissolved
in PBS containing cyclodextrin (5% (w/v) cyclodextrin in
PBS/1 mg of SOS) to enhance the solubility of SOS.
48
P-GFLG-SOS, P-(GFLG-Mce6)-Fab′ , and P-(GFLG-SOS)-
Fab′ were prepared in PBS. Other samples (Mce6 and
P-GFLG-Mce6) were prepared in DI water. All stock
(48) Alley, M. C.; Hollingshead, M. G.; Dykes, D. J.; Waud, W. R.
Human tumor xenograft models in NCI drug development. In
Anticancer Drug DeVelopment Guide: Preclinical Screening,
Clinical Trials, and ApproVal, 2nd ed.; Teicher, B. A., Andrews,
P. A, Eds.; Humana Press: Totowa, NJ, 2004; pp 125-152.
Table 2. Characterization of Fab′ -Targeted HPMA
Copolymer-Mce6/-SOS Immunoconjugates
structures
wt %
drug:polymer:Fab′
a
molecular ratio
drug:polymer:Fab′
mol wt
(kDa)
b
P-(GFLG-Mce6)-Fab′ 2.1:21.1:76.8 2:1:1 64
P-(GFLG-SOS)-Fab′ 1.6:23.5:74.9 5:1:1 72
a Mce6 and SOS contents determined by UV spectrophotometry
in methanol: ε395 ) 158000 M
-1 cm
-1 for Mce6, ε358 ) 33000 M
-1
cm
-1 for SOS. Protein content was determined by Lowry assay.
b Calculated from the composition of polymer (molecular ratio of
drug, polymer, and Fab′ ).
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by UV spectrophotometry. All stock solutions were freshly
prepared and gradually diluted with RPMI 1640 culture
medium before use.
Confocal Microscopy. Fifty thousand OVCAR-3 cells
were subcultured into an eight-chamber slide and incubated
for 2 days at 37 °C in a humidiﬁed atmosphere of 5% CO2.
The cells in each chamber were exposed to ﬂuorescein-
labeled copolymer conjugates (at 20 µM FITC equivalent)
at 37 °Cf o r1hi nt h edark. Cells were ﬁxed with 2%
paraformaldehyde for 20 min at room temperature and
washed twice with PBS. The chamber slide was covered with
a cover slide utilizing antifade reagent (Molecular Probes).
The cell internalization of ﬂuorescently labeled HPMA
copolymer conjugates was imaged using a Zeiss (Thornwood,
NY) LSM 510 confocal imaging system.
Flow Cytometry. OVCAR-3 cells (75,000 cells/well) were
seeded into a 24-well plate and incubated for 24 h at 37 °C
in a humidiﬁed atmosphere of 5% CO2. Cells in each well
were exposed to the ﬂuorescein-labeled copolymer conju-
gates (at 20 µM FITC equivalent) at 37 °Cf o r1hi nt h e
dark. The medium was removed. The cell monolayer was
rinsed twice with ice-cold PBS and detached from the well
surface by incubation with TrypLE Express (Gibco) for 2
min. All steps were carried out on ice to minimize efﬂux of
the sample. The cells were suspended with ice-cold PBS
containing 0.2% FBS, maintained in suspension on ice in
the dark and processed for ﬂow cytometry utilizing FACScan
Scheme 2. Synthesis and Chemical Structure of HPMA Copolymer-Mce6/-SOS Conjugates Containing Maleimide Group
[P-(GFLG-Mce6)-MAL and P-(GFLG-SOS)-MAL, Respectively]
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collected per sample. Control cells were not exposed to the
sample to assess the endogenous ﬂuorescence of the cells.
Additional experiments were performed at 0 °C (on ice)
to demonstrate the surface binding of targeted conjugates.
OVCAR-3 cells, growth medium and the ﬂuorescein-labeled
conjugates (at 10 µM FITC equivalent) were precooled on
ice before experiments. The cells were exposed to conjugates
for 2 h, then the medium containing conjugates was
discarded, and cells were washed extensively with cold PBS
and processed for ﬂow cytometry as described above.
Cytotoxicity Bioassays. The drug concentration that
inhibited cell growth by 50% compared with control cells
(IC50) was determined using a modiﬁed 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
49
Cells were seeded in 96-well ﬂat bottom microplates at a
density of 10,000 cells/well in 200 µL of RPMI 1640
medium and allowed to grow for ∼30 h. The cells were then
exposed to various concentrations of each free drug alone
(Mce6 and SOS), each nontargeted copolymer conjugate (P-
GFLG-Mce6 and P-GFLG-SOS), each targeted copolymer
conjugate [P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ ],
or their sequential combinations (n ) 6 in single experiment).
The different treatment protocols are shown in Scheme 3.
During the cells’ exposure to drug(s), they were incubated
at 37 °C in a humidiﬁed atmosphere of 5% CO2 and in the
dark condition. After 4 days of exposure for SOS and its
conjugates or 1 day of exposure for Mce6 and its conjugates,
the drugs were removed, cells were washed with warm PBS
and the medium (300 µL) was replaced. For cell growth
inhibition studies using Mce6, P-GFLG-Mce6, or P-(GFLG-
Mce6)-Fab′ (alone or in combinations), the cells were
irradiated with three tungsten halogen lamps through a 650
nm band-pass ﬁlter at 3.0 mW/cm
2 for 30 min. After an
additional 1 day or 4 days in culture for SOS and its
conjugates or for Mce6 and its conjugates, respectively,
medium was removed and replaced with 100 µL of fresh
medium and 10 µL of sterile-ﬁltered MTT solution (5 mg/
mL in PBS). After incubating for 24 h, 150 µL of 20% (w/
v) sodium dodecyl sulfate in water was added to each well
and incubated overnight. The following day, the absorbance
of each well was read at 570 nm with a reference wavelength
at 630 nm. Untreated cells served as a 100% cell viability
control, and the media served as background reference.
Growth inhibition was expressed as the growth of drug-
treated cells related to that of untreated control cells.
Determination of Drug Interaction and Combination
Index. In combination treatment studies, OVCAR-3 cells
were treated with a dose range of SOS for 4 days followed
by a dose range of Mce6 for 1 day, and irradiated for 30
min (n ) 6 in single experiment), as shown in Scheme 3.
After each step the drug was removed and the cells were
washed with warm PBS. Drug interaction and CI were
determined using median-effect analysis according to the
method of Chou and Talalay.
41,42 The median-effect equation
describes dose-effect relationships, which is expressed by
fa/fu ) (D/Dm)
m or log(fa/fu) ) m log(D) - m log(Dm) where
fa and fu are the fraction affected [1 - (absorbance of
treatment well - average of absorbance of blanks)/(average
of absorbance of untreated cell wells - average of absor-
bance of blanks)] and unaffected (fu ) 1 - fa) by the dose
or concentration D, Dm is the median-effect dose (IC50) that
inhibits the cell growth by 50%, and m is the coefﬁcient
signifying the shape of the dose-effect relationship. Based
on the logarithmic conversion, the plot of x ) log(D) versus
y ) log(fa/fu) is called the median-effect plot and Dm is
calculated from the antilog of the x-intercept. The CI
describes the interaction between two drugs and quantitates
the synergism, antagonism or additive effects. The CI is
determined by the equation CI ) [(D)1/(Dx)1] + [(D)2/(Dx)2]
where (Dx)1 and (Dx)2 are the doses of drug 1 alone and drug
2 alone that inhibit the cell growth x%, respectively. (D)1
and (D)2 are for doses in combination that also inhibit x%.
The CI values were calculated for different values of fa and
plotting the CI values as a function of fa values, using
CompuSyn software (ComboSyn Inc., Paramus, NJ). In the
fa-CI plot, CI < 1, ) 1, and > 1 indicate synergism,
additivity, and antagonism, respectively.
Statistical Analysis. All mean values are presented as
means ( standard deviation (n ) 6 in a single experiment).
(49) Hansen, M. B.; Nielsen, S. E.; Berg, K. Re-examination and further
development of a precise and rapid dye method for measuring
cell growth/cell kill. J. Immunol. Methods 1989, 119 (2), 203–
210.
Scheme 3. Experimental Protocols Used in the Cytotoxicity Study
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Characteristics of HPMA Copolymer-Mce6/-SOS
Conjugates. The structures of HPMA copolymer conjugates,
P-GFLG-Mce6, P-GFLG-SOS, P-(GFLG-Mce6)-Fab′ , and
P-(GFLG-SOS)-Fab′ , are shown in Scheme 1. The drugs,
Mce6 and SOS, were bound to the HPMA copolymer
backbone via a GFLG spacer, stable in the bloodstream, but
susceptible to enzymatically catalyzed hydrolysis in the
lysosomal compartment of the cells.
50-52 For Fab′ attach-
ment, the amino groups of APMA monomer units in HPMA
copolymer precursors were ﬁrst converted to maleimido
groups by reaction with a heterobifunctional agent, SMCC
(Scheme 2), followed by attachment of Fab′ via thioether
bonds. For some experiments, ﬂuorescently labeled conju-
gates were synthesized. In nontargeted conjugates, the 5-SFX
was attached to amino groups of APMA monomer units. The
Fab′ -targeted conjugates were labeled by the reaction of
5-SFX with the ﬁnal conjugates.
The characteristics of HPMA copolymer precursors, non-
targeted HPMA copolymer conjugates, Fab′ -targeted HPMA
copolymer conjugates, and ﬂuorescently labeled conjugates
are summarized in Tables 1 and 2. P-GFLG-Mce6, P-GFLG-
SOS, P-(GFLG-Mce6)-Fab′ , and P-(GFLG-SOS)-Fab′ con-
jugates contained 2.9, 3.4, 2.0, and 5.0 drug molecules per
macromolecule, respectively. P-(GFLG-Mce6)-Fab′ and P-
(GFLG-SOS)-Fab′ had drug:polymer:Fab′ molecular ratios
of approximately 2:1:1 and 5:1:1, respectively. The Mw of
Fab′ -targeted copolymer conjugates were 2.2 to 2.8 times
higher than those of nontargeted conjugates.
Intracellular Uptake of Fluorescein-Labeled Fab′ -Tar-
geted HPMA Copolymer Conjugates. Unlike low molecular
weight drugs that enter cells by diffusion through the plasma
membrane, macromolecules are internalized within membrane-
limited vesicles in the process of endocytosis. Several basic
internalization mechanisms, clathrin-mediated endocytosis,
caveolae-mediated endocytosis, clathrin- and caveolin-
independent endocytosis, and macropinocytosis have been
identiﬁed.
53,54 To a greater or lesser extent, two or more
distinct mechanisms coexist when a single cell type internal-
izes macromolecule-drug conjugates.
55
Studies on the subcellular fate of HPMA copolymer-drug
conjugates demonstrated that the conjugates are lysosomo-
tropic and will accumulate in the lysosomal compartment
of the cell. Tijerina et al., using subcellular fractionation,
determined the localization of a considerable fraction of
HPMA copolymer-Mce6 conjugates in the lysosomal com-
partment of human ovarian carcinoma A2780 cells.
56 Ome-
lyanenko et al. used pH dependent ﬂuorescence of FITC to
display the lysosomotropism of FITC-labeled HPMA co-
polymers containing N-acylated galactosamine in HepG2
hepatocarcinoma cells.
57
Recently,theuptakemechanismofHPMAcopolymer-DOX
conjugate in human ovarian carcinoma OVCAR-3 cells was
studied by confocal ﬂuorescence microscopy and by colo-
calization experiments with substrates speciﬁc for a particular
internalization mechanism. The results suggested that the
HPMA copolymer-DOX conjugate is internalized via both
clathrin- and caveolae-mediated endocytosis.
55
The biorecognition and cellular uptake of P-(GFLG-Mce6)-
(Fab′ -FITC) and P-(GFLG-SOS)-(Fab′ -FITC) was studied
using confocal microscopy (Figure 1) and ﬂow cytometry
(Figures 2 and 3). Nontargeted conjugates, P-(GFLG-Mce6)-
FITC and P-(GFLG-SOS)-FITC, served as controls. After a
1 h exposure of OVCAR-3 cells to HPMA copolymer
conjugates at 37 °C, the intracellular concentrations of
targeted polymer conjugates containing Mce6 and SOS were
signiﬁcantly higher when compared to nontargeted conju-
gates. Both confocal microscopy images and ﬂow cytometry
proﬁles displayed very similar results.
However, at 37 °C two processes, biorecognition at surface
and internalization by endocytosis, are operative. To clearly
demonstrate the biorecognition of targeted conjugates by the
CD47 antigen, OVCAR-3 cells were exposed to conjugates
at 0 °C. Flow cytometry data at 0 °C, at conditions that
suppress endocytosis, demonstrated the biorecognition of
P-(GFLG-Mce6)-Fab′ and P-(GFLG-SOS)-Fab′ conjugates
by OVCAR-3 cells (Figure 3). After incubation of OVCAR-3
cells with targeted and nontargeted conjugates for 2 h, no
increase in ﬂuorescent intensity (when compared to controls
not exposed to any conjugates) in cells incubated with
P-GFLG-Mce6 and P-GFLG-SOS was observed. In contrast,
higher ﬂuorescent intensities were detected in cells incubated
with targeted (Fab′ containing) conjugates P-(GFLG-Mce6)-
Fab′ and P-(GFLG-SOS)-Fab′ . Presumably, the ﬂuorescent
signals were derived from membrane associated conjugates
as a result of Fab′ -CD47 interactions.
These results indicated the biorecognition of HPMA
copolymer conjugates containing the Fab′ antibody fragment
by OVCAR-3 cells. The results of confocal microscopy are
(50) Kopec ˇek, J. Controlled biodegradability of polymerssa key to
drug delivery systems. Biomaterials 1984, 5 (1), 19–25.
(51) Kopec ˇek, J.; Rejmanova ´, P. Enzymatically Degradable Bonds in
Synthetic Polymers. In Controlled Drug DeliVery; Bruck, S. D.,
Ed.; CRC Press: Boca Raton, FL, 1983; pp 81-124.
(52) Rejmanova ´, P.; Pohl, J; Baudys ˇ, M.; Kostka, V.; Kopec ˇek, J.
Polymers containing enzymatically degradable bonds. 8. Degrada-
tion of oligopeptide sequences in N-(2-hydroxypropyl)methacryl-
amide copolymers by bovine spleen cathepsin B. Makromol.
Chem. 1983, 184 (10), 2009–2020.
(53) Roth, M. G. Clathrin-mediated endocytosis before ﬂuorescent
proteins. Nat. ReV. Mol. Cell Biol. 2006, 7 (1), 63–68.
(54) Soldati, T.; Schliwa, M. Powering membrane trafﬁc in endocytosis
and recycling. Nat. ReV. Mol. Cell Biol. 2006, 7 (12), 897–908.
(55) Liu, J.; Pan, H.; Kopec ˇkova ´, P.; Kopec ˇek, J. Internalization and
Subcellular Fate of HPMA Copolymer-Doxorubicin Conjugates;
International Symposium on Polymer Therapeutics ISPT-07,
Berlin, Germany, February 19-21, 2007; Proceedings, p 49.
(56) Tijerina, M.; Kopec ˇkova ´, P.; Kopec ˇek, J. Correlation of subcellular
compartmentalization of HPMA copolymer-Mce6 conjugates with
therapeutic activity in human ovarian carcinoma cells. Pharm.
Res. 2003, 20, 728–737.
(57) Omelyanenko, V.; Kopec ˇkova ´, P.; Gentry, C.; Kopec ˇek, J.
Targetable HPMA copolymer-adriamycin conjugates. Recognition,
internalization, and subcellular fate. J. Controlled Release 1998,
53 (1-3), 25–37.
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polymer conjugates via receptor-mediated endocytosis, and
of the nontargeted conjugates, containing hydrophobic drugs,
by ﬂuid-phase pinocytosis and adsorptive pinocytosis,
concurrently.
The data are consistent with our previous results on the
determination of binding constants of OV-TL16 antibody
targeted HPMA copolymers toward OVCAR-3 cells.
58 The
afﬁnity constant, Ka, of free antibody was 8 × 10
-8 M
-1,
whereas the Ka for the P-(GG-Mce6)-Fab′ was 3 × 10
-8 M
-1.
The minor decrease in the afﬁnity may be a result of chemical
modiﬁcation and/or steric hindrance of the polymer chain
upon the formation of the antibody-antigen complex.
In Vitro Inhibition of OVCAR-3 Cell Growth by
Drugs as Single Agents. The growth inhibitory effects of
Mce6, SOS, P-GFLG-Mce6, P-GFLG-SOS, P-(GFLG-
Mce6)-Fab′ , and P-(GFLG-SOS)-Fab′ as single agents on
OVCAR-3 cells were evaluated after drug exposure using
the MTT assay. The IC50 values for the free drugs,
nontargeted and targeted HPMA copolymer conjugates are
shown in Table 3. The 1-day Mce6 exposure and 4-day
SOS exposure have been selected based on preliminary
experiments on the relationship between exposure time
and cell inhibition effect (data not shown). After 1-day
Mce6 exposure and 4-day SOS exposure, the cells were
more susceptible to Mce6 than SOS about 2 times. It is
Figure 1. Confocal image of ﬁxed OVCAR-3 cells incubated with ﬂuorescein-labeled HPMA copolymer conjugates in
RPMI 1640 culture medium for1hi nt h edark. (A) P-(GFLG-Mce6)-FITC, (B) P-(GFLG-SOS)-FITC, (C)
P-(GFLG-Mce6)-(Fab′ -FITC), and (D) P-(GFLG-SOS)-(Fab′ -FITC).
Figure 2. Flow cytometry proﬁles of OVCAR-3 cells incubated with ﬂuorescein-labeled HPMA copolymer conjugates in
RPMI 1640 culture medium for1hi nt h edark. (A) Control cells, (B) P-(GFLG-Mce6)-FITC, (C) P-(GFLG-SOS)-FITC,
(D) P-(GFLG-SOS)-(Fab′ -FITC), (E) P-(GFLG-Mce6)-(Fab′ -FITC).
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of SOS toward OVCAR-3 cells and toward the human
A498 renal cell line.
31 Our previous study on human renal
A498 cells demonstrated that free SOS and P-GFLG-SOS
conjugates were effective individually and in combination
with free DOX and P-GFLG-DOX or free Mce6 and
P-GFLG- Mce6, respectively.
31 The IC50 values for Mce6
toward both cell types (OVCAR-3 and A498
31) were
similar. However, SOS was very effective toward A498
cells (IC50 ) 3n M ) ,
31 but its activity toward OVCAR-3
was about 670 times lower. These data are consistent with
the results of the NCI anticancer drug screen consisting
of a panel of 60 human cancer cell lines. Rivera et al.
showed that after a 2-day continuous exposure to SOS,
OVCAR-3 cells were less sensitive to SOS than the A498
cells.
35 These results reﬂect the different p53 status in
these cell lines. The inhibitory effect of SOS is mediated
through p53; the disruption of the p53-HDM-2 interactions
results in increasing p53 accumulation in tumor cells.
33
It was demonstrated that the p53 status of A498 cells and
OVCAR-3 cells is wild-type and mutant, respectively.
59
However, the study of the p53 gene in human ovarian
carcinoma cell lines by Yaginuma and Westphal showed
that the wild-type p53 protein was detectable in OVCAR-3
cells by immunoprecipitation analysis.
60 These reports
indicated that OVCAR-3 cells can be inhibited by higher
concentrations of SOS, but have a considerably lower
sensitivity when compared to the A498 cell line.
The IC50 doses of nontargeted conjugates, P-GFLG-
Mce6 and P-GFLG-SOS, were higher than those of free
Mce6 and SOS, respectively. These results reﬂect the
different mechanisms of cell entry of free drugs vs
copolymer conjugates.
61 In contrast, the targeted P-(GFLG-
Mce6)-Fab′ conjugate was 2 and 9 times more effective
than Mce6 and P-GFLG-Mce6, respectively. The cytotox-
icity data with Mce6 conjugates were in agreement with
biorecognition data and internalization mechanisms (Fig-
ures 1, 2 and 3). There was a discrepancy in data obtained
for P-(GFLG-SOS)-Fab′ . This conjugate showed faster
internalization (Figure 1) and moderately better biorec-
ognition (Figure 2) than P-GFLG-SOS; however, it
possessed a slightly weaker inhibitory effect than P-GFLG-
SOS (Table 3). One explanation may be in the long drug
exposure time. After long exposure times the intracellular
drug content of targeted and nontargeted conjugates may
be similar.
62 Furthermore, the efﬁcacies of SOS and its
conjugates might be limited by the problem of SOS
trafﬁcking to the subcellular compartments where p53 is
(58) Omelyanenko, V.; Kopec ˇkova ´, P.; Gentry, C.; Shiah, J. G.;
Kopec ˇek, J. HPMA copolymer-anticancer drug-OV-TL16 anti-
body conjugates. 1. Inﬂuence of the method of synthesis on the
binding afﬁnity to OVCAR-3 ovarian carcinoma cells in vitro. J.
Drug Targeting 1996, 3 (5), 357–373.
(59) O’Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.;
Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.;
Weinstein, J. N.; Friend, S.; Fornace, A. J., Jr.; Kohn, K. W.
Characterization of the p53 tumor suppressor pathway in cell lines
of the National Cancer Institute anticancer drug screen and
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Figure 3. Flow cytometry proﬁles of OVCAR-3 cells incubated with ﬂuorescein-labeled HPMA copolymer conjugates in
RPMI 1640 culture medium for2hi nt h edark at 0 °C. (A) Control cells, (B) P-(GFLG-Mce6)-FITC, (C)
P-(GFLG-SOS)-FITC, (D) P-(GFLG-SOS)-(Fab′ -FITC), (E) P-(GFLG-Mce6)-(Fab′ -FITC).
Table 3. IC50 Values for Mce6, SOS, and HPMA
Copolymer-Mce6/-SOS Conjugates against OVCAR-3
Cells
drug
incubation
time (days)
IC50 or Dm
(µM)
a
Mce6 1 3.34 ( 0.43
P-GFLG-Mce6 1 12.5 ( 1.06
P-(GFLG-Mce6)-Fab′ 1 1.35 ( 0.10
SOS 4 2.02 ( 0.17
P-GFLG-SOS 4 32.9 ( 4.94
P-(GFLG-SOS)-Fab′ 4 43.8 ( 2.90
a Dm is the median-effect dose that inhibits the cell growth by
50%. IC50 and Dm values are the means ( SEM (n ) 6 in single
experiment).
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Subcellular targeting is very important for some active
agents and macromolecular therapeutics that have to be
transported to their assigned cell organelles. Once those
molecules are delivered to the cytosol, various approaches
to locate drugs in a particular subcellular organelle have
been performed, such as the use of nuclear localization
peptides,
56,64 cell-penetrating peptides,
65 lipophilic cat-
ionic moieties,
2 and mitochondrial localization agents.
66
The OA-3 surface antigen (CD47 or IAP) was chosen as
delivery target in this study because it is overexpressed in
about 90% of the ovarian tumors and only weakly expressed
in normal tissue.
39 A panel of anti-CD47 mAbs used in the
study of Mawby et al., such as NBTS/BRIC-125 (BRIC-
125), NBTS/BRIC-126 (BRIC-126) and NBTS/BRIC-154
(BRIC-154), showed an extremely broad tissue distribution,
not only in ovarian carcinomas studied, but also in all
hematopoietic cells, mesenchyme and epithelia at multiple
sites.
38 On the contrary, the tissue distribution of
125I-labeled
OV-TL16 mAb in OVCAR-3 bearing nude mice 48 h after
iv injection studied by Boerman et al. demonstrated that
125I-
labeled OV-TL16 mAb possessed tumor/nontumor ratio of
about 3-15.
39 Furthermore, the mAb OV-TL3 used by
Campbell et al. to deﬁne OA3 showed little or no reactivity
with normal tissues but reacted with most ovarian carcino-
mas.
40 Slobbe et al. studied the structure of OV-TL3 and
OV-TL16 antibodies and reported that both mAbs are able
to bind to same epitopic regions on the ovarian carcinoma
membrane antigen OA3, although structurally different in
their VH regions.
67
The basis for the difference between mAbs used in the
study of Mawby et al. and Boerman et al. or Campbell et
al. is unknown and deserves further investigation. One
possibility is that an unusual amino acid sequence in the
OA3 isoforms is expressed in ovarian cancer cells, and
that OV-TL3 and OV-TL16 recognize epitopes in this
sequence.
38
In Vitro Inhibition of OVCAR-3 Cell Growth with
Drug Combinations. The investigation of possible syner-
gistic, additive, or antagonistic effects of sequential combina-
tionsofSOS+Mce6,P-GFLG-SOS+P-GFLG-Mce6,orP-(GFLG-
SOS)-Fab′ +P-(GFLG-Mce6)-Fab′ againsttheovariancarcinoma
OVCAR-3 cell line was performed in Vitro by exposing cells
to SOS or its conjugates for 4 days, followed by exposure
of cells to Mce6 or its conjugates for 1 day, and ﬁnally, a 30
min irradiation. This sequential combination was chosen
because the optimal exposure times of SOS/P-GFLG-SOS/
P-(GFLG-SOS)-Fab′ and Mce6/P-GFLG-Mce6/P-(GFLG-
Mce6)-Fab′ were different (4 days for SOS and 1 day for
Mce6), as mentioned above. The dose ratios of each
combination (Table 4) were based on their respective IC50
concentrations from Table 3 as a series of 2-fold dilutions
from 4 to 0.03125 times IC50. Figure 4 shows the composite
dose-response curves and median-effect plots of OVCAR-3
cells, indicating the antiproliferative effects of single agents
and their combinations. The dose-response curves for
combined treatment were obtained by plotting % cell viability
(y) vs the combined dose of two single agents (x). The
median-effect plots of single agents and combinations were
derived from the linear part of dose-response curves. All
of the combination treatments showed antiproliferative
activities toward OVCAR-3 cells. The dose ratio and Dm
values of the combination treatments are shown in Table 4.
The IC50 dose of each drug in combinations was signiﬁcantly
lower than those of each drug as single agents (compare
Tables 3 and 4). These results clearly indicate that all of the
combination treatments were effective against OVCAR-3
cells.
The CI analysis was used to assess the drug-drug
interaction of the sequential combinations of free drugs,
nontargeted and targeted copolymer conjugates toward
OVCAR-3 cells in Vitro.
41,42 In the CI analysis, values of
CI < 1, CI ) 1, and CI > 1 indicate synergy, additivity,
and antagonism, respectively. Figure 5 shows the combina-
tion index plots (fa-CI plots) over all inhibition effect levels
(fa ) 0.05-0.95 or 5-95% of inhibition effect) in OVCAR-3
(63) Shmueli, A.; Oren, M. Regulation of p53 by Mdm2: fate is in the
numbers. Mol. Cell 2004, 13 (1), 4–5.
(64) Tijerina, M.; Kopec ˇkova ´, P.; Kopec ˇek, J. Mechanisms of cyto-
toxicity in human ovarian carcinoma cells exposed to free Mce6
or HPMA copolymer-Mce6 conjugates. Photochem. Photobiol.
2003, 77 (6), 645–652.
(65) Nori, A.; Jensen, K. D.; Tijerina, M.; Kopec ˇkova ´, P.; Kopec ˇek,
J. Tat-conjugated synthetic macromolecules facilitate cytoplasmic
drug delivery to human ovarian carcinoma cells. Bioconjugate
Chem. 2003, 14 (1), 44–50.
(66) Callahan, J.; Kopec ˇek, J. Semitelechelic HPMA copolymers
functionalized with triphenylphosphonium as drug carriers for
membrane transduction and mitochondrial localization. Biomac-
romolecules 2006, 7 (8), 2347–2356.
(67) Slobbe, R.; Poels, L.; ten Dam, G.; Boerman, O.; Nieland, L.;
Leunissen, J.; Ramaekers, F.; van Eys, G. Analysis of idiotope
structure of ovarian cancer antibodies: recognition of the same
epitope by two monoclonal antibodies differing mainly in their
heavy chain variable sequences. Clin. Exp. Immunol. 1994, 98
(1), 95–103.
Table 4. Dose Ratios and IC50 Doses in Combinations of
Free Drugs (SOS+Mce6), Nontargeted Copolymer
Conjugates (P-GFLG-SOS+P-GFLG-Mce6), and
Targeted Copolymer Conjugates
[P-(GFLG-SOS)-Fab′ +P-(GFLG-Mce6)-Fab′ ] in OVCAR-3
Cells
drug combination
drug A drug B
dose
ratio
Dm (µM)
a
(dose A + dose B)
b
SOS Mce6 1:1.61 0.096 ( 0.0077
(0.037 + 0.059)
P-GFLG-SOS P-GFLG-Mce6 1:0.38 1.69 ( 0.22
(1.22 + 0.47)
P-(GFLG-SOS)-
Fab′
P-(GFLG-Mce6)-
Fab′
1:0.031 1.70 ( 0.38
(1.65 + 0.051)
a Dm values are the means ( SEM (n ) 6 in single
experiment).
b Doses of drug A and drug B were calculated
approximately from the Dm of each combination and dose ratio.
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P-GFLG-SOS+P-GFLG-Mce6 yield CI values lower than 1
over the entire range of cytotoxicity, indicating very strong
synergistic to synergistic effects. The P-(GFLG-SOS)-
Fab′ +P-(GFLG-Mce6)-Fab′ combination also displayed a
strong synergism for fa values up to about 0.85, but showed
synergistic effect and nearly additive effect at fa ) 0.9 and
0.95, respectively.
The drug interactions may depend on the differences of
drugs in the combination, such as physicochemical properties,
the mechanisms of action, and the drug exposure schedules.
All these differences may result in different antitumor
activities. SOS and Mce6 are hydrophobic low molecular
weight molecules, but both have different mechanisms and
sites of action. SOS acts on p53 and DNA while Mce6 can
cause damage to biological molecules by generation of
reactive oxygen species. In our previous study, we compared
the simultaneous combination of P-GFLG-SOS+P-GFLG-
Mce6 to SOS+Mce6 against the human renal A498 carcinoma
cell line. After 16 h cell exposure to the combinations, both
combinations displayed synergism for fa up to 0.8, but
showed slight antagonism and near additivity at fa ) 0.95.
31
Many researchers have studied the antitumor activities
following different drug exposure schedules. For example,
the simultaneous and sequential exposures of irofulven with
oxaliplatin or cisplatin against human breast, colon, and
ovarian cancer cell lines showed that the sequence oxaliplatin
Figure 4. Dose response curves and median-effect plots of OVCAR-3 cells treated with Mce6, SOS, P-GFLG-Mce6,
P-GFLG-SOS, P-(GFLG-Mce6)-Fab′ , and P-(GFLG-SOS)-Fab′ as single agents and sequential combinations at
constant ratios of their respective IC50 concentrations. Bars represent standard error (n ) 6 in single experiment).
articles Hongrapipat et al.
708 MOLECULAR PHARMACEUTICS VOL. 5, NO. 5followed by irofulven displayed better synergistic effect than
the other schedules.
68
Conclusion
Combination chemotherapy and PDT with free SOS and
Mce6, their nontargeted and Fab′ -targeted HPMA copolymer
conjugates in human ovarian carcinoma OVCAR-3 cells was
evaluated. Sequential combinations of these therapeutics
produced very strong synergism to nearly additivity in the
treatment of OVCAR-3 cells. The synergistic effects ranked
in the order P-GFLG-SOS+P-GFLG-Mce6 > SOS+Mce6
> P-(GFLG-SOS)-Fab′ +P-(GFLG-Mce6)-Fab′ . These data
support continued in ViVo investigations of SOS and Mce6
combinations to determine the antitumor activity for the
treatment of ovarian cancer.
Abbreviations Used
AIBN, 2,2′ -azobisisobutyronitrile; APMA, N-(3-amino-
propyl)methacrylamide hydrochloride; CI, combination in-
dex; Dm, median-effect dose; DI, deionized; DIPEA, N,N′ -
diisopropylethylamine; DMAP, 4-dimethylaminopyridine;
DMF, N,N-dimethylformamide; DOX, doxorubicin; EPR,
enhanced permeability and retention; GFLG, glycylphenyl-
alanylleucylglycine; HPMA, N-(2-hydroxypropyl)methacryl-
amide; IC50, concentration that inhibited cell growth by 50%
as compared with control cell growth; MA, methacryloyl;
mAb, monoclonal antibody; Mw, weight average molecular
weight; Mce6, mesochlorin e6 monoethylenediamine diso-
dium salt; MTT assay, modiﬁed 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay; ONp, p-nitro-
phenoxy; P, HPMA copolymer backbone; PDT, photodynamic
therapy; P-GFLG-Mce6, HPMA copolymer-Mce6 conjugate;
P-(GFLG-Mce6)-Fab′ , antibody Fab′ fragment targeted HPMA
copolymer-Mce6 conjugate; P-GFLG-ONp, HPMA copoly-
mer precursor containing reactive p-nitrophenyl ester groups
at side chain termini; P-GFLG-SOS, HPMA copolymer-SOS
conjugate; P-(GFLG-SOS)-Fab′ , antibody Fab′ fragment
targeted HPMA copolymer-SOS conjugate; 5-SFX, 6-(ﬂuo-
rescein-5-carboxamido)hexanoic acid succinimidyl ester;
SMCC, succinimidyl trans-4-(maleimidomethyl)cyclohex-
ane-1-carboxylate; SOS, 2,5-bis(5-hydroxymethyl-2-thienyl)-
furan; THF, tetrahydrofuran.
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Figure 5. Combination index plots (fa-CI plots) obtained
from median-effect analysis. Chemotherapeutic drugs and
their HPMA copolymer conjugates were gradually diluted
at the ratio of their IC50 values as a series of 2-fold
dilutions from 4 to 0.03125 times IC50 and OVCAR-3 cells
exposed to drugs sequentially as described in Materials
and Methods. CI < 1, ) 1 and > 1 indicate synergism,
additive effect, and antagonism, respectively. The vertical
bars indicate the 95% conﬁdence intervals based on
sequential deletion analysis (SDA) and can be generated
by using CompuSyn software.
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